<DOC>
	<DOC>NCT00979459</DOC>
	<brief_summary>This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single 80 mg dose of the dry filled capsule (DFC) and film coated tablet (FCT) formulations of MK-1006 will be similar.</brief_summary>
	<brief_title>A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>is a male or a female of nonchild bearing potential has type 2 diabetes (T2D) and is either being treated with diet and exercise alone or with a single or combination oral antihyperglycemic agent(s) has been a nonsmoker for at least 6 months has a history of stroke, chronic seizures, or major neurological disorder has a history of major endocrine (except T2D), gastrointestinal, cardiovascular, blood, liver, immune, kidney, respiratory, or genitourinary abnormalities or diseases has a history of cancer, except certain skin or cervical cancers or cancer that was successfully treated more than 10 years prior to screening has unstable or rapidly progressing diabetic retinopathy and/or neuropathy has had an eye infection or other inflammation of the eye in the 2 weeks prior to screening has glaucoma or is blind has had incisional eye surgery in the last 6 months or laser eye surgery in the last 3 months (Lasik is permitted) has a history of type 1 diabetes has symptomatic coronary artery disease consumes excessive amounts of alcohol and/or caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>